Epitalon

Peptide

Recorded history of Epitalon — FDA records, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on reported sources; source classification alone does not authenticate a vote tally.

Latest published federal record

Under review — eligibility not established here

source-event date Apr 16, 2026

Recorded status is not an eligibility determination. PCAC recommendations are advisory. Category 1 is a nomination under FDA evaluation, distinct from the final 503A Bulks List established by rulemaking. FDA’s January 2025 interim policy describes conditional enforcement discretion, not FDA approval or unconditional permission. Its Category 1 conditions include manufacturer registration, a valid certificate of analysis and all other applicable 503A conditions; that policy does not apply to Category 2. Assess the exact substance, form and route against the applicable monograph, approved-drug-component, final-list and interim-policy provisions.

FDA January 2025 interim guidance ↗

Tracker collector’s last successful poll: not available on this public page. The aggregate polling signal on the tracker index covers multiple sources.

Per-substance authority reconciliation: no documented date is provided here. A recent source event or poll does not establish complete coverage of FDA updates.

Source-event dates and recent source polls do not establish that each substance’s current eligibility has been reverified.

We do not sell, source, or supply Epitalon. This is a monitoring record from public government sources — not a product, and not advice.

Federal history

Apr 16, 2026PCAC reviewFederal
PCAC under-review tag recorded
Stored event summary — not a current eligibility determination: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
Note: PCAC recommendations are advisory. Category 1 is a nomination under FDA evaluation, distinct from the final 503A Bulks List established by rulemaking. FDA’s January 2025 interim policy describes conditional enforcement discretion, not FDA approval or unconditional permission. Its Category 1 conditions include manufacturer registration, a valid certificate of analysis and all other applicable 503A conditions; that policy does not apply to Category 2. Assess the exact substance, form and route against the applicable monograph, approved-drug-component, final-list and interim-policy provisions.
2026-07361 · primary source ↗

State overlays

No MSR event recorded in the published state history for Epitalon. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.

Track Epitalon changes

Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.

Get the free Brief →

← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.

Get regulatory changes as they publish

We scan all 50 state legislatures daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.

Free · unsubscribe in one click · we never sell your address